SCHEMBL1285397

SCHEMBL1285397

O=c1[nH]c2ccsc2c(=O)o1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 1/20 0.46
F2 P00734 1/20 0.46
CFD P00746 1/20 0.46
DAO P14920 1/20 0.39
OGT O15294 1/20 0.39
TSHR P16473 2/20 0.38
HTT P42858 1/20 0.38
MAPT P10636 2/20 0.37
ALDH1A1 P00352 1/20 0.36
NOS1 P29475 4/20 0.35
NOS2 P35228 3/20 0.35
NOS3 P29474 2/20 0.35
LMNA P02545 1/20 0.35
CYP1A2 P05177 1/20 0.35
ADRA2A P08913 1/20 0.35
THPO P40225 1/20 0.35
BLM P54132 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
ELANE P08246 1/20 0.35
NPC1 O15118 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16152549 0.71
SCHEMBL988816 0.70 PDPK1 (0.50) PDPK1DAOTSHRHTTALDH1A1
SCHEMBL7073592 0.68 OGT (0.39) PDPK1DAOOGTTSHRMAPT
SCHEMBL1522407 0.68 TNKS2 (0.47) F2CFDDAOALDH1A1ELANE
SCHEMBL189932 0.67 PDPK1 (0.48) PDPK1DAOTSHRHTTALDH1A1
SCHEMBL14498482 0.65 NOS1 (0.41) F2CFDOGTTSHRNOS1
SCHEMBL13558618 0.65 PARP1 (0.53) PDPK1DAOTSHRHTTALDH1A1
SCHEMBL20630920 0.64 PDPK1 (0.50) PDPK1DAOTSHRHTTALDH1A1
SCHEMBL2588876 0.64 ALDH1A1 (0.52) PDPK1DAOTSHRHTTMAPT
SCHEMBL1523074 0.64 ERCC5 (0.54) F2CFDOGTMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120483994-B Tryptanthrin compound and preparation method and application thereof SHAANXI UNIVERSITY OF CHINESE MEDICINE (CN) 2026-05-29 CN disclosed
US-12454525-B2 IL4I1 inhibitors and methods of use MERCK SHARP & DOHME LLC (US) 2025-10-28 US disclosed
CN-120483994-A Tryptanthrin compound and preparation method and application thereof 陕西中医药大学 2025-08-15 CN disclosed
CN-115836054-B IL4I1 inhibitors and methods of use 默沙东有限责任公司 2024-12-10 CN disclosed
CN-116888127-A Tri-fused ring HPK1 inhibitor and application thereof 轩竹生物科技股份有限公司 2023-10-13 CN disclosed
US-20230183214-A1 IL4I1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC 2023-06-15 US disclosed
US-20230183214-A1 IL4I1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC 2023-06-15 US disclosed
US-20230183214-A1 IL4I1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC 2023-06-15 US disclosed
CN-115836054-A IL4I1 inhibitors and methods of use 默沙东有限责任公司 2023-03-21 CN disclosed
EP-4146644-A1 IL4I1 INHIBITORS AND METHODS OF USE Merck Sharp & Dohme LLC (US) 2023-03-15 EP disclosed
EP-0059391-A1 Imidazodiazepines, process for their preparation and pharmaceutical compositions containing them F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1982-09-08 EP disclosed
US-4346032-A ANTIDOTES TO OVERDOSES OF BENZODIAZEPINE TRANQUILIZERS HOFFMANN-LA ROCHE INC. (US) 1982-08-24 US disclosed
US-4346034-A Process for preparing imidazodiazepines HOFFMANN-LA ROCHE INC. (US) 1982-08-24 US disclosed
US-4346031-A Process for preparing imidazodiazepines HOFFMANN-LA ROCHE INC. (US) 1982-08-24 US disclosed
US-4346030-A ANTIDOTES FOR OVERDOSES OF BENZODIAZEPINE TRANQUILIZERS HOFFMANN-LA ROCHE INC. (US) 1982-08-24 US disclosed
US-4346035-A Process for preparing imidazodiazepines HOFFMANN-LA ROCHE INC. (US) 1982-08-24 US disclosed
US-4346036-A ALKYLATION; AMIDATION; TRANQUILIZER ANTAGONIST HOFFMANN-LA ROCHE INC. (US) 1982-08-24 US disclosed
US-4346033-A Thienodiazepinone and benzodiazepinone intermediates HOFFMANN-LA ROCHE INC. (US) 1982-08-24 US disclosed
US-4316839-A Imidazodiazepine derivatives HOFFMAN-LA ROCHE INC. (US) 1982-02-23 US disclosed
EP-0027214-A1 Imidazodiazepine derivatives, process and intermediates for their preparation, medicaments containing them and their therapeutic application F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1981-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183214-A1 IL4I1 INHIBITORS AND METHODS OF USE IL4I1, IL4, IL2 PDPK1 3620/4885F2 2129/4885CFD 1495/4885
US-12454525-B2 IL4I1 inhibitors and methods of use IL4I1, IL4, IL2 PDPK1 3620/4885F2 2129/4885CFD 1495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.